- Home
- DSGN vs OPFI Comparison
DSGN vs OPFI Comparison
Compare DSGN & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- OPFI
- Stock Information
- Founded
- DSGN 2017
- OPFI 2009
- Country
- DSGN United States
- OPFI United States
- Employees
- DSGN N/A
- OPFI N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- OPFI Finance: Consumer Services
- Sector
- DSGN Health Care
- OPFI Finance
- Exchange
- DSGN Nasdaq
- OPFI Nasdaq
- Market Cap
- DSGN 348.2M
- OPFI 290.9M
- IPO Year
- DSGN 2021
- OPFI N/A
- Fundamental
- Price
- DSGN $4.91
- OPFI $11.30
- Analyst Decision
- DSGN Hold
- OPFI Buy
- Analyst Count
- DSGN 3
- OPFI 2
- Target Price
- DSGN $7.00
- OPFI $7.50
- AVG Volume (30 Days)
- DSGN 126.2K
- OPFI 2.6M
- Earning Date
- DSGN 03-18-2025
- OPFI 03-05-2025
- Dividend Yield
- DSGN N/A
- OPFI 1.06%
- EPS Growth
- DSGN N/A
- OPFI 775.86
- EPS
- DSGN N/A
- OPFI 0.38
- Revenue
- DSGN N/A
- OPFI $260,661,000.00
- Revenue This Year
- DSGN N/A
- OPFI N/A
- Revenue Next Year
- DSGN N/A
- OPFI $6.51
- P/E Ratio
- DSGN N/A
- OPFI $29.86
- Revenue Growth
- DSGN N/A
- OPFI 23.85
- 52 Week Low
- DSGN $2.45
- OPFI $2.35
- 52 Week High
- DSGN $7.77
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- DSGN 53.37
- OPFI 41.42
- Support Level
- DSGN $3.58
- OPFI $11.16
- Resistance Level
- DSGN $5.17
- OPFI $15.30
- Average True Range (ATR)
- DSGN 0.40
- OPFI 1.38
- MACD
- DSGN 0.11
- OPFI -0.66
- Stochastic Oscillator
- DSGN 83.65
- OPFI 2.13
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.